Search Results for: Malattia Arteriosa Periferica (PAD) - Indicazioni su diagnosi e gestione

Condizione rara, ma grave, causata da depositi di proteine anomale

Evita il rischio di infezione accidentale. Oms, la Tbc la malattia più letale nel 2024

Un terzo dei pazienti finisce in una casa di cura entro 3 anni

Un terzo dei pazienti finisce in una casa di cura entro 3 anni

Senza aumento delle false diagnosi. Uno in più per 1.000 individui

Ascierto, il 50% dei pazienti metastatici sopravvive a 10 anni dalla diagnosi

Objective
This study aimed to assess the effect of home-based exercise interventions on walking performance in patients with peripheral artery disease (PAD) and intermittent claudication (IC).

Design
Systematic review and meta-analysis.

Data sources
We searched the Medline, Web of Science, Embase, Scopus and Cochrane Library databases to identify randomised controlled trials of patients with PAD and IC published in English up to August 2024.

Eligibility criteria
Randomised controlled trials of patients who participated in home-based exercise interventions and were assessed for walking performance were eligible for inclusion. Studies without available data were excluded.

Data extraction and synthesis
We analysed the pooled effect size on walking performance based on the standardised mean differences between groups. A leave-one-out sensitivity analysis was performed to ensure the robustness of the findings.

Results
A total of eight studies were included in the meta-analysis. The duration of interventions in the included studies ranged from 6 to 52 weeks. In the pooled analysis, compared with control groups, the home-based exercise intervention groups showed improved pain-free walking distance (standardised mean difference 0.67, 95% CI 0.20 to 1.15), and maximal walking distance (0.47, 0.05 to 0.89). The overall heterogeneity score of pain-free walking distance was I2=83% (p

Una circolare dei farmacisti, attese le indicazioni operative

Analisi potrebbe individuare primissimi segni cellule cancerose

La disfunzionalità dell’adipe si riflette sui tessuti arteriosi, cardiaci e renali e queste interconnessioni rappresentano una sfida importante per il Ssn, ma anche un’opportunità per migliorare la presa in cura dei pazienti con patologie complesse

Rinviato a metà gennaio voto su piano revisione Rete oncologica

Positivo a influenza 28% dei test; presenti Covid e rhinovirus

Introduction
Foot ulcers are one of the most serious complications of diabetes, leading to significant risks on amputation and mortality. Peripheral arterial disease (PAD) is an important factor for the development and the outcome of diabetic foot ulcers (DFU). Although prompt and accurate detection of PAD is critical to reduce complications, its diagnosis can be challenging with currently used bedside tests (such as ankle–brachial index and toe pressure) due to medial arterial calcification. A new and promising bedside test for the detection of PAD is the maximal systolic acceleration (ACCmax), measured by duplex ultrasonography (DUS). The primary aim of this study is to assess the diagnostic performance of the ACCmax to detect PAD in patients with DFU, in comparison with commonly used bedside tests. Secondary aims include the correlation between diagnostic test accuracy and patient comorbidities. Tertiary objectives focus on collecting (follow-up) data for prognostic evaluation, such as ulcer healing, revascularisation feasibility, amputation risk, cardiovascular events and mortality.

Methods and analysis
A multicentre prospective diagnostic accuracy study with 198 patients will be conducted to assess the diagnostic performance of multiple index tests to detect PAD in patients with DFU, with special emphasis on ACCmax. A full lower limb arterial DUS will serve as reference test.

Ethics and dissemination
Study protocol approval was gained from the Medical Ethical Committee Leiden/Den Haag/Delft and registered at ClinicalTrials.gov. The findings of this study will be reported through peer-reviewed publications and (inter)national conferences.

Trial registration number
NCT05646147.